G. Stussi

Discipline

Psychologie (1)

Type de document

Articles (5)

Co-auteur

Date

Source

Mot-clé

puits (4) survie (4) Treatment (4) Rates (4) Survival (4) Rates (4) risque (3) Risk (3) Population (3) Patients (3) Human beings (3) Patients (3) Number (3) analyse (2) famille (2) dose (2) âge (2) procès (2) Cases (2) Cell transplantation (2) Swiss (2) Adjustable rate mortgages (2) Months (2) Bone marrow (2) Families (2) Blood (2) Arm (2) Older people (2) Age (2) Addition (2)

Documents écrit par G. Stussi (5) | parle de G. Stussi (0)

Genetic and phenotypic attributes of splenic marginal zone lymphoma.
F. Bonfiglio et al. (3 févr. 2022)
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
J. Janssen et al. (7 févr. 2021)
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.
G. Huls et al. (22 sept. 2020)
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016.
J.R. Passweg et al. (2018)
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries.
J.R. Passweg et al. (2013)